CA3024278A1 - Use of carbamate compound in order to preventatively treat headaches - Google Patents

Use of carbamate compound in order to preventatively treat headaches Download PDF

Info

Publication number
CA3024278A1
CA3024278A1 CA3024278A CA3024278A CA3024278A1 CA 3024278 A1 CA3024278 A1 CA 3024278A1 CA 3024278 A CA3024278 A CA 3024278A CA 3024278 A CA3024278 A CA 3024278A CA 3024278 A1 CA3024278 A1 CA 3024278A1
Authority
CA
Canada
Prior art keywords
migraine
headache
pharmaceutical composition
carbamate compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024278A
Other languages
English (en)
French (fr)
Inventor
Hye Won Shin
Yoon Kyung Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CA3024278A1 publication Critical patent/CA3024278A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3024278A 2016-05-19 2017-05-18 Use of carbamate compound in order to preventatively treat headaches Pending CA3024278A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061374 2016-05-19
KR10-2016-0061374 2016-05-19
PCT/KR2017/005171 WO2017200316A1 (ko) 2016-05-19 2017-05-18 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
CA3024278A1 true CA3024278A1 (en) 2017-11-23

Family

ID=60325338

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024278A Pending CA3024278A1 (en) 2016-05-19 2017-05-18 Use of carbamate compound in order to preventatively treat headaches

Country Status (8)

Country Link
US (2) US10456376B2 (enExample)
EP (1) EP3459541B1 (enExample)
JP (1) JP6986521B2 (enExample)
KR (1) KR102421006B1 (enExample)
CN (1) CN109310670B (enExample)
CA (1) CA3024278A1 (enExample)
ES (1) ES2893456T3 (enExample)
WO (1) WO2017200316A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CA3113052A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus
CA3112166A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CA3157788A1 (en) * 2019-11-22 2021-05-27 Ji Hye Lee Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
US4349556A (en) * 1976-06-24 1982-09-14 Bayer Aktiengesellschaft Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes
EP1461309A1 (en) * 2001-12-21 2004-09-29 Ortho-McNeil Pharmaceutical, Inc. Process for preparing 2-(substituted phenyl) - 2 - hydroxy-ethyl carbamates
US20060194873A1 (en) * 2004-09-16 2006-08-31 Choi Yong M Methods of treating epileptogenesis and epilepsy
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9108368B2 (en) 2009-10-16 2015-08-18 Novartis Ag Apparatus and method for transporting contact lenses through dipping baths

Also Published As

Publication number Publication date
WO2017200316A1 (ko) 2017-11-23
JP2019516726A (ja) 2019-06-20
CN109310670A (zh) 2019-02-05
CN109310670B (zh) 2022-03-29
US10456376B2 (en) 2019-10-29
ES2893456T3 (es) 2022-02-09
EP3459541A4 (en) 2020-01-08
KR102421006B1 (ko) 2022-07-14
US20200009113A1 (en) 2020-01-09
EP3459541A1 (en) 2019-03-27
EP3459541B1 (en) 2021-09-15
US20190216780A1 (en) 2019-07-18
JP6986521B2 (ja) 2021-12-22
KR20170131240A (ko) 2017-11-29

Similar Documents

Publication Publication Date Title
US20200009113A1 (en) Use of carbamate compound in order to preventatively treat headaches
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
IL274431B1 (en) Use of a carbamate compound to reduce or treat developmental disorders including fragile X syndrome, Engelmann syndrome, or Rett syndrome
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
HK40003858A (en) Use of carbamate compound in order to preventatively treat headaches
HK40003858B (en) Use of carbamate compound in order to preventatively treat headaches
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220421

EEER Examination request

Effective date: 20220421

EEER Examination request

Effective date: 20220421

EEER Examination request

Effective date: 20220421

EEER Examination request

Effective date: 20220421